41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.
27 citations
,
April 2005 in “Journal of Chemotherapy” This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.
32 citations
,
October 2004 in “Pharmacotherapy” In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.
March 2016 in “International Journal of Infectious Diseases” This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.
15 citations
,
January 2014 in “Dermatology” This study found a relatively low prevalence of cutaneous reactions in chronic hepatitis C patients treated with peginterferon alfa and ribavirin, with reactions correlated to age and treatment duration.